摘要
目的研究新药TJ0711对肾血管性高血压大鼠的肾脏保护作用及可能的作用机制。方法 36只Wistar大鼠随机分成6组,1组为假手术组,其余5组均为二肾一夹(two-kidney one-clip,2K1C)肾血管性高血压模型,再分为模型组、卡维地洛组、TJ0711低剂量组、TJ0711中剂量组和TJ0711高剂量组,每组各6只。给药8周后处死大鼠,检测血清尿素氮(BUN)和肌酐(Scr)、尿蛋白/尿肌酐(urine protein/creatinine ratio)和血清一氧化氮(nitric oxide,NO)水平。取夹侧肾组织行免疫组化检测肾组织中缺氧诱导因子1α(HIF-1α)和Vasohibin的表达。Western blot法测定肾组织中内皮型一氧化氮合酶(eNOS)、HIF-1α和Vasohibin的表达。结果与模型组相比,治疗组各组大鼠血肌酐无明显变化,但血清尿素氮和尿蛋白/尿肌酐水平明显降低,同时血清NO明显增多(P<0.05),eNOS蛋白表达亦增加(P<0.05)。免疫组化和Western blot检测均显示,与模型组相比,TJ0711低、中剂量组HIF-1α和Vasohibin表达减少(均P<0.05),而卡维地洛和TJ0711高剂量组无明显变化。结论新药TJ0711能明显降低2K1C肾血管性高血压大鼠的蛋白尿和尿素氮水平,其对肾血管性高血压大鼠肾脏的保护机制可能与其上调eNOS表达、增加NO,同时下调HIF-1α和Vasohibin表达有关。
Objective To investigate renal protective effects of TJ0711 on rat two-kidney one-clip hypertension model and the mechanism. Methods Thirty-six Wistar rats were randomly divided into six groups:sham group, and five groups of renovascular hypertension(model group,carvedilol group,low dose of TJ0711 group,moderate dose of TJ0711 group,and high dose of TJ0711 group), n= 6 each. Renovascular hypertension model was established by two-kidney one-clip method and the rats were sacrificed eight weeks after administration. Urea nitrogen,ereatinine,urinary protein/urine creatinine,and serum NO were determined. HIFla and Vasohibin were detected from renal cortical tissue by using immunohistochemical staining,and eNOS, HIF-la and Vasohibin by using Western blot. Results There was no significant change in creatinine. Compared to model group, urea nitrogen and urinary protein/urine creatinine were decreased in groups of intervention,while serum NO and eNOS protein were increased(P〈0.05). Compared to model group, HIF-la and Vasohibin were down-regulated in low dose of TJ0711 and moderate dose of TJ0711 groups(P〈0. 05). HIF-la and Vasohibin were slightly up-regulated in high dose of TJ0711 group(P 〉0.05). Conclusion TJ0711 can obviously reduce urinary protein and urea nitrogen in rat model of two-kidney one-clip renovascular hypertension probably by up-regulating the expression of eNOS and NO,and simultaneously down-regulating the expression of HIF-la and Vasohibin.
出处
《华中科技大学学报(医学版)》
CAS
CSCD
北大核心
2012年第2期142-146,共5页
Acta Medicinae Universitatis Scientiae et Technologiae Huazhong
基金
重大新药创制科技重大专项(No.2009ZX09103-146)
国家自然科学基金资助项目(No.81170686)
教育部科学技术研究重大项目(No.311028)